Skip to main content

Table 3 Grade ≥ 3 AEs regardless of attribution to navoximod

From: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  Navoximod 50 mg BID (n = 1) Navoximod 100 mg BID (n = 3) Navoximod 200 mg BID (n = 3) Navoximod 400 mg BID (n = 3) Navoximod 600 mg BID (n = 3) Navoximod 800 mg BID (n = 6) All Patients 21/28 day schedule (N = 19) Navoximod continuous schedule 600 mg BID (n = 3) All Patients (N = 22)
Any adverse event 1 (100%) 3 (100%) 1 (33%) 3 (100%) 2 (67%) 2 (33%) 12 (63%) 2 (67%) 14 (63%)
Neoplasm progression 1 (33%) 1 (33%) 1 (33%) 3 (16%) 3 (14%)
AST increased 1 (33%) 1 (33%)   2 (11%) 2 (9%)
Anemia 1 (33%) 1 (5%) 1 (5%)
Ascites 1 (33%) 1 (5%) 1 (5%)
Dysphagia 1 (33%)   1 (5%) 1 (5%)
Hypokalemia   1 (17%) 1 (5%) 1 (5%)
Hypotension   1 (17%) 1 (5%) 1 (5%)
Lower GI hemorrhage   1 (17%) 1 (5%) 1 (5%)
Mental status changes 1 (33%)   1 (5%) 1 (5%)
Muscular weakness 1 (33%) 1 (5%) 1 (5%)
Peripheral neuropathy 1 (33%) 1 (5%) 1 (5%)
Acute pancreatitis 1 (33%) 1 (5%) 1 (5%)
Pneumonia 1 (33%) 1 (5%) 1 (5%)
Small Intestinal Obstruction 1 (33%) 1 (5%) 1 (5%)
Tumor pain 1 (33%) 1 (5%) 1 (5%)
Bloody discharge 1 (33%) 1 (5%)
Diverticulitis 1 (33%) 1 (5%)
Lymphopenia 1 (33%) 1 (5%)